Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 4, 2006, Pages 393-401

  Rolland, Yannève ^a   Demeule, Michel ^a   Béliveau, Richard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Detachment; Endothelial cell; Fibronectin; Matrix metalloproteinase; Melanotransferrin; Plasminogen; Tissue type plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; EPIGALLOCATECHIN; ILOMASTAT; MELANOTRANSFERRIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; HUMAN CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

CELL ADHESION; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; NEOPLASM PROTEINS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; SOLUBILITY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33646525425     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.03.006     Document Type: Article

References (85)

1. Brown J.P., Woodbury R.G., Hart C.E., Hellstrom I., and Hellstrom K.E. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 539-543
2. Brown J.P., Hewick R.M., Hellstrom I., et al. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature 296 (1982) 171-173
3. Alemany R., Vila M.R., Franci C., et al. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J. Cell Sci. 104 Pt. 4 (1993) 1155-1162
4. Food M.R., Rothenberger S., Gabathuler R., et al. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 269 (1994) 3034-3040
5. Richardson D.R. The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur. J. Biochem. 267 (2000) 1290-1298
6. Michaud-Levesque J., Demeule M., and Beliveau R. Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion. Exp. Cell Res. 308 2 (2005) 479-490
7. Brown L.F., Detmar M., Claffey K., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79 (1997) 233-269
8. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
9. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
10. Dvorak H.F. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am. J. Pathol. 162 (2003) 1747-1757
11. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
12. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
13. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 15-18
14. Castellino F.J., and Ploplis V.A. Structure and function of the plasminogen/plasmin system. Thromb. Haemostasis 93 (2005) 647-654
15. Andreasen P.A., Nielsen L.S., Grondahl-Hansen J., et al. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J. 3 (1984) 51-56
16. Markus G. The relevance of plasminogen activators to neoplastic growth, A review of recent literature. Enzyme 40 (1988) 158-172
17. Moser T.L., Stack M.S., Wahl M.L., and Pizzo S.V. The mechanism of action of angiostatin: can you teach an old dog new tricks?. Thromb. Haemostasis 87 (2002) 394-401
18. Parfyonova Y.V., Plekhanova O.S., and Tkachuk V.A. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry 67 (2002) 119-134 (Mosc)
19. Vassalli J.D., and Pepper M.S. Tumour biology, Membrane proteases in focus. Nature 370 (1994) 14-15
20. Reinartz J., Schafer B., Batrla R., Klein C.E., and Kramer M.D. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp. Cell Res. 220 (1995) 274-282
21. Carmeliet P., Moons L., Lijnen R., et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17 (1997) 439-444
22. Carmeliet P., and Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb. Res. 91 (1998) 255-285
23. Sato Y., Okamura K., Morimoto A., et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp. Cell Res. 204 (1993) 223-229
24. Herbert J.M., Lamarche I., and Carmeliet P. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J. Biol. Chem. 272 (1997) 23585-23591
25. Herbert J.M., and Carmeliet P. Involvement of u-PA in the anti-apoptotic activity of TGFbeta for vascular smooth muscle cells. FEBS Lett. 413 (1997) 401-404
26. Liotta L.A., Goldfarb R.H., Brundage R., et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41 (1981) 4629-4636
27. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta 823 (1985) 35-65
28. He C.S., Wilhelm S.M., Pentland A.P., et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2632-2636
29. Mochan E., and Keler T. Plasmin degradation of cartilage proteoglycan. Biochim. Biophys. Acta 800 (1984) 312-315
30. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1104-1117
31. Forget M.A., Desrosiers R.R., and Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can. J. Physiol. Pharmacol. 77 (1999) 465-480
32. Kleiner D.E., and Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43 (1999) S42-S51 (Suppl.)
33. Frisch S.M., and Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124 (1994) 619-626
34. Houard X., Monnot C., Dive V., Corvol P., and Pagano M. Vascular smooth muscle cells efficiently activate a new proteinase cascade involving plasminogen and fibronectin. J. Cell. Biochem. 88 (2003) 1188-1201
35. Nagase H., Enghild J.J., Suzuki K., and Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29 (1990) 5783-5789
36. Sechler J.L., and Schwarzbauer J.E. Control of cell cycle progression by fibronectin matrix architecture. J. Biol. Chem. 273 (1998) 25533-25536
37. Hadden H.L., and Henke C.A. Induction of lung fibroblast apoptosis by soluble fibronectin peptides. Am. J. Respir. Crit. Care Med. 162 (2000) 1553-1560
38. Buckley C.D., Pilling D., Henriquez N.V., et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397 (1999) 534-539
39. Verderio E.A., Telci D., Okoye A., Melino G., and Griffin M. A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J. Biol. Chem. 278 (2003) 42604-42614
40. Jeong J., Han I., Lim Y., et al. Rat embryo fibroblasts require both the cell-binding and the heparin-binding domains of fibronectin for survival. Biochem. J. 356 (2001) 531-537
41. Bonnefoy A., and Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb. Res. 98 (2000) 323-332
42. Demeule M., Bertrand Y., Michaud-Levesque J., et al. Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. Blood 102 (2003) 1723-1731
43. Michaud-Levesque J., Rolland Y., Demeule M., Bertrand Y., and Beliveau R. Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. Biochim. Biophys. Acta 1743 (2005) 243-253
44. Guan J.L., and Hynes R.O. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell 60 (1990) 53-61
45. Ge M., Tang G., Ryan T.J., and Malik A.B. Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis. J. Clin. Invest. 90 (1992) 2508-2516
46. Davis G.E., Pintar-Allen K.A., Salazar R., and Maxwell S.A. Matrix metalloproteinase-1 and-9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J. Cell Sci. 114 (2001) 917-930
47. Levi M., Roem D., Kamp A.M., et al. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb. Haemostasis 69 (1993) 141-146
48. Syrovets T., and Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol. Life Sci. 61 (2004) 873-885
49. Moses M.A. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15 (1997) 180-189
50. Carlevaro M.F., Albini A., Ribatti D., et al. Transferrin promotes endothelial cell migration and invasion: implication in cartilage neovascularization. J. Cell Biol. 136 (1997) 1375-1384
51. Sala R., Jefferies W.A., Walker B., et al. The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo. Eur. J. Cell Biol. 81 (2002) 599-607
52. Shimamura M., Yamamoto Y., Ashino H., et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer 111 (2004) 111-116
53. Bezault J., Bhimani R., Wiprovnick J., and Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54 (1994) 2310-2312
54. Yoo Y.C., Watanabe S., Watanabe R., et al. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88 (1997) 184-190
55. Iigo M., Kuhara T., Ushida Y., et al. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis 17 (1999) 35-40
56. Norrby K., Mattsby-Baltzer I., Innocenti M., and Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int. J. Cancer 91 (2001) 236-240
57. Duffy M.J. Plasminogen activators and cancer. Blood Coagul, Fibrinolysis 1 (1990) 681-687
58. Kramer M.D., Reinartz J., Brunner G., and Schirrmacher V. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis 14 (1994) 210-222
59. Pintucci G., Bikfalvi A., Klein S., and Rifkin D.B. Angiogenesis and the fibrinolytic system. Semin. Thromb. Hemostasis 22 (1996) 517-524
60. Bell W.R. The fibrinolytic system in neoplasia. Semin. Thromb. Hemostasis 22 (1996) 459-478
61. Sugimura M., Kobayashi H., and Terao T. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells. Gynecol. Oncol. 52 (1994) 337-346
62. Rakoczi I., Wiman B., and Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim. Biophys. Acta 540 (1978) 295-300
63. Rouy D., and Angles-Cano E. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro, Role of alpha 2-antiplasmin. Biochem. J. 271 (1990) 51-57
64. Longstaff C., and Gaffney P.J. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 30 (1991) 979-986
65. Mazzieri R., Masiero L., Zanetta L., et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 16 (1997) 2319-2332
66. Jespersen J., Gram J., and Astrup T. The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition. Thromb. Res. 41 (1986) 395-404
67. Gaffney P.J. Fibrin(-ogen) interactions with plasmin. Haemostasis 6 (1977) 2-25
68. Grimard M. Evidence for high-molecular weight active peptides originating from porcine plasmin autolysis. Biochimie 58 (1976) 1409-1412
69. Meilhac O., Ho-Tin-Noe B., Houard X., et al. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J. 17 (2003) 1301-1303
70. Reijerkerk A., Mosnier L.O., Kranenburg O., et al. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol. Cancer Res. 1 (2003) 561-568
71. Reijerkerk A., Voest E.E., and Gebbink M.F. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur. J. Cancer. 36 (2000) 1695-1705
72. Monea S., Lehti K., Keski-Oja J., and Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 192 (2002) 160-170
73. Okumura Y., Sato H., Seiki M., and Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin, A possible cell surface activator. FEBS Lett. 402 (1997) 181-184
74. Baramova E.N., Bajou K., Remacle A., et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 405 (1997) 157-162
75. Takano A., Hirata A., Inomata Y., et al. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am. J. Ophthalmol. (2005)
76. Levkau B., Kenagy R.D., Karsan A., et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ. 9 (2002) 1360-1367
77. De Petro G., Tavian D., Copeta A., et al. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 58 (1998) 2234-2239
78. Lindgren M., Johansson M., Sandstrom J., et al. VEGF and tPA co-expressed in malignant glioma. Acta Oncol. 36 (1997) 615-618
79. Hackel C., Czerniak B., Ayala A.G., Radig K., and Roessner A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer 79 (1997) 53-58
80. Gris J.C., Schved J.F., Marty-Double C., Mauboussin J.M., and Balmes P. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. Chest 104 (1993) 8-13
81. Yamashita J., Inada K., Yamashita S., et al. Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer. Int. J. Clin. Lab. Res. 21 (1992) 227-230
82. de-Witte J.H., Sweep C.G., Klijn J.G., et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br. J. Cancer 80 (1999) 286-294
83. Grebenschikov N., Geurts-Moespot A., De Witte H., et al. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int. J. Biol. Markers 12 (1997) 6-14
84. Kim S.J., Shiba E., Kobayashi T., et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin. Cancer Res. 4 (1998) 177-182
85. Pepper M.S., Ferrara N., Orci L., and Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181 (1991) 902-906